Natixis Advisors
RLAY icon

Natixis Advisors’s Relay Therapeutics RLAY Stock Holding History

Natixis Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,888
Closed -$378K – 1502
2022
Q3 		$378K Buy
16,888
+118
+0.7% +$2.59K ﹤0.01% 1344
2022
Q2 		$281K Buy
16,770
+228
+1% +$4.89K ﹤0.01% 1391
2022
Q1 		$495K Sell
16,542
-90
-0.5% -$2.18K ﹤0.01% 1290
2021
Q4 		$511K Buy
16,632
+6,179
+59% +$195K ﹤0.01% 1241
2021
Q3 		$330K Sell
10,453
-8,782
-46% -$296K ﹤0.01% 1261
2021
Q2 		$704K Hold
19,235
– – ﹤0.01% 1162
2021
Q1 		$664K Buy
+19,235
New +$835K ﹤0.01% 1124

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Natixis Advisors's RLAY Position: Q4 2022 in Review

Natixis Advisors sold out of Relay Therapeutics (RLAY) in Q4 2022, closing a stake of 16,888 shares — an estimated $378K sold.

Natixis Advisors first reported a position in RLAY in Q1 2021 and held it in 7 quarters. The position peaked at $704K in Q2 2021. 165 funds tracked by Wall St. Rank hold RLAY as of Q4 2022.

  • Natixis Advisors reported no remaining Relay Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Natixis Advisors sold 16,888 Relay Therapeutics shares in Q4 2022, an estimated $378K.
  • Natixis Advisors first reported a position in Relay Therapeutics in Q1 2021 and held it in 7 quarters.
  • Natixis Advisors's Relay Therapeutics position peaked at $704K in Q2 2021.
  • 165 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2022.

Based on Natixis Advisors's 13F filing for Q4 2022, filed 27 Jan 2023.